For secondary myeloid neoplasms, ICC 2022 highlights specific mutations indicative of therapy-related myeloid neoplasms or those arising from pre-existing conditions such as TP53, ASXL1, EZH2, and DNMT3A. This evidence concerns the gene ASXL1 and myeloid neoplasm.